Literature DB >> 16684223

Prevalence of hepatitis E virus infection in regular hemodialysis patients.

Kan Kikuchi1, Takumi Yoshida, Naoki Kimata, Chifumi Sato, Takashi Akiba.   

Abstract

The percentage of patients infected with blood-borne diseases, including hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, is high in patients undergoing hemodialysis regularly. Hepatitis E virus (HEV) is transmitted via the fecal-oral route, and blood-borne HEV infection has also been reported recently. On the basis of these findings, we investigated the actual status of HEV infection in regular hemodialysis patients. Out of 1077 patients undergoing hemodialysis at two key hospitals and three outpatient hemodialysis clinics, 300 were randomly selected as the subjects. Among these 300 hemodialysis patients, 19.0% were IgG-type anti-HEV antibody-positive. The percentage of HEV-infected patients increased with patient age and it was particularly high in patients 40 years of age or older. The percent IgG-type anti-HEV antibody positivity was not significantly different (P = 0.14) between anti-HCV antibody-positive patients (27.8%) and anti-HCV antibody-negative patients (17.8%). The percentage of HEV-infected patients among the hemodialysis patients was higher than that previously reported among patients with healthy kidneys. No correlation was observed between the percentage of HEV-infected patients and HCV infection incidence or a history of blood transfusion. The percent IgG-type anti-HEV antibody positivities were significantly different among the facilities. It was impossible to specify the route of infection, and the correlation between the incidence of infection and hemodialysis therapy was not clear. Because more routes of infection are possible for patients undergoing dialysis than for persons with normal kidney function, it seems necessary to analyze the significance of infection incidence, the route of infection and infection prevention measures.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16684223     DOI: 10.1111/j.1744-9987.2006.00363.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  7 in total

1.  Hepatitis E in hemodialysis and kidney transplant patients in south-east Italy.

Authors:  Gaetano Scotto; Filippo Aucella; Giuseppe Grandaliano; Domenico Martinelli; Mario Querques; Antonio Gesuete; Barbara Infante; Paolo Delli Carri; Salvatore Massa; Giovanna Salatino; Fabio Bulla; Vincenzina Fazio
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

2.  Patterns in the prevalence of hepatitis C virus infection at the start of hemodialysis in Japan.

Authors:  Yuko Iwasa; Shigeru Otsubo; Orie Sugi; Keitaro Sato; Yukari Asamiya; Aya Eguchi; Tomihito Iwasaki; Nami Matsuda; Kan Kikuchi; Norisato Ikebe; Naoko Miwa; Naoki Kimata; Keiko Uchida; Shigeharu Uchida; Kosaku Nitta; Takashi Akiba
Journal:  Clin Exp Nephrol       Date:  2008-01-05       Impact factor: 2.801

3.  Hepatitis E: a complex and global disease.

Authors:  E Pelosi; I Clarke
Journal:  Emerg Health Threats J       Date:  2008-11-07

Review 4.  Hepatitis E Virus in Industrialized Countries: The Silent Threat.

Authors:  Pilar Clemente-Casares; Carlota Ramos-Romero; Eugenio Ramirez-Gonzalez; Antonio Mas
Journal:  Biomed Res Int       Date:  2016-12-14       Impact factor: 3.411

5.  Prevalence of anti-hepatitis E virus IgG antibodies in sera from hemodialysis patients in Tripoli, Lebanon.

Authors:  Mohamad Bachar Ismail; Imad Al Kassaa; Dima El Safadi; Sarah Al Omari; Hassan Mallat; Fouad Dabboussi; Monzer Hamze
Journal:  PLoS One       Date:  2020-05-18       Impact factor: 3.240

Review 6.  Hepatitis E virus and blood transfusion safety.

Authors:  Hao Bi; Ru Yang; Chunchen Wu; Jianbo Xia
Journal:  Epidemiol Infect       Date:  2020-06-29       Impact factor: 2.451

7.  Anti-Hepatitis E Antibody in Hemodialysis Patients in Isfahan, Iran: Prevalence and Risk Factors.

Authors:  Seyed Moayed Alavian; Behrooz Ataei; Ali Ebrahimi; Omid Pirhaji; Roya Azad; Behrooz Olya; Amir Mohammad Ataei
Journal:  Hepat Mon       Date:  2015-09-08       Impact factor: 0.660

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.